PATENT CLAIM ANALYSIS

Application Number: 15987993
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-01
Patent Classification: ["435", "320100"]

Abstract:
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.

Claim (Index 28):
The modified AAV capsid protein of  claim 26 , wherein the non-serine amino acid residue is selected from the group consisting of phenylalanine (F), valine (V), histidine (H), isoleucine (I), alanine (A), leucine (L) aspartic acid (D), asparagine (N), glutamic acid (E), arginine (R) and isoleucine (I).

Metadata:
- Claim Count in Document: 56.0
- Percentile: 93.0
- Lexical Diversity: 1.84375
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14214011', '15444235', '14401442', '13840224', '13854011']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.787224243587245
- 35 USC 102 Novelty (BERT): 0.6787421350729741
- Combined Prediction Score: 0.7763760327358179
- Mean Citation Score: 662.089968
- Max Citation Score: 792.17664
- Similarity Product: 670.6897925115968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test